Abstract
The magnetite nanoparticles (Fe3O4) are very promising nanomaterials to be applied as drug delivery due to their excellent superparamagnetic, biocompatibility and easily modified surface properties. Those properties are influenced by the structure and size of the material which can be controlled by studying the evolution of crystal growth. The purpose of this research is to study the evolution of crystal growth of magnetite nanoparticles in the hydrothermal system and determine the crystal growth kinetics using the Oriented Attachment Growth model. Magnetite nanoparticles were synthesized using a hydrothermal method from FeCl3, citrate, urea and polyethylene glycol at 210?C for 1 - 12 hours at a various concentration of FeCl3 (0.05 M, 0.10 M, and 0.15 M). The characterizations were conducted by X-ray Diffraction (XRD), Transmission Electron Microscope (TEM), Particle size analyzer (PSA), and Vibrating Sample Magnetometer (VSM). The XRD difractogram indicated that the magnetite was begun to form at 3.5 hours synthesis. The crystallinity and the crystal size of magnetite rose with reaction time. The diameter of magnetite crystals was in the range of 9.4-30 nm. Characterization by TEM showed that the particles were formed from a smaller particles which were then agglomerated. The PSA characterization showed that the distribution of diameter size enlarged with the enhancement of concentrations. VSM result showed that the magnetite nanoparticle has superparamagnetic properties. The magnetite crystal growth can be fitted by the Oriented Attachment Growth model with an error of 29%.
Highlights
Cancer is a major public health problem and the second leading cause of death globally. e latest update from the IARC (International Agency for Reseach on Cancer), the cancer burden rises to 18.1 million new cases and responsible for an estimated 9.6 million deaths in 2018 [1]
The drug delivery has been developed as a new method for cancer therapy. e principle of this method is delivering the drug into the target site using a nanoparticle as a “vehicle”. e advantages of nano drug delivery compared to conventional medication methods are (1) it has the ability to treat the specific targets in the body, (2) the dose of the drug is reduced, (3) the concentration of the drug at the nontarget sites is reduced, and (4) the side effects caused by drug toxicity in cells/nontarget tissues are reduced [2]
Magnetite nanoparticle (Fe3O4) is one of the materials that isa very promising candidate for being applied to drug delivery system due to its superparamagnetic and highbiocompatibility properties [3]. e controlled size and the morphology of nanoparticles are needed in drug delivery system because it affects the accessibility, the time residence in the bloodstream and the toxicity in the human body [4, 5]
Summary
Cancer is a major public health problem and the second leading cause of death globally. e latest update from the IARC (International Agency for Reseach on Cancer), the cancer burden rises to 18.1 million new cases and responsible for an estimated 9.6 million deaths in 2018 [1]. An underst anding of the factors that affectsthe crystal growth kinetics and microstructure development in nanocrystals is fundamental to control the nanoparticle properties [6]. It is important for the tailoring process of the nanoparticles to have uniform size and morphology [6]. 2. EXPERIMENTAL is study consisted of three main stages: (1) magnetite nanoparticles preparation using the hydrothermal method, (2) characterizationsusing XRD (X-ray diffraction), TEM (transmission electron microscope), PSA (particle size analyzer), and VSM (vibrating sample magnetometer) and (3) modeling the kinetics of magnetite crystal growth. E black precipitates were characterized by XRD, TEM, PSA, BET analyzer and VSM
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
